Lipid Target: LDL, Non? High-Density Lipoprotein Cholesterol, or HDL?

调脂治疗的靶点：LDL、非高密度脂蛋白胆固醇，还是HDL ？

youdao

On at least one visit during the 10-year period, 34.2% had elevated total cholesterol, 9.4% had low HDL, and 47.8% had elevated non-HDL, the researchers note.

研究者指出，在过去10年期间至少有一次调查，有34.2%患者总胆固醇曾升高，9.4%高密度脂蛋白降低和47.8%非高密度脂蛋白升高。

youdao

As expected, mipomersen also resulted in significant reductions in app B, total cholesterol, and non-HDL cholesterol.

FORBES: FDA Review Raises Safety Concerns About Mipomersen

The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia